LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Open

SectorHealthcare

30.17 -5.01

Buy Sell

Overview

Share price change

24h

Current

Min

29.86

Max

31.68

Key metrics
By Trading Economics
Income	-200M -314M
Sales	428K 2M
Profit margin	-15,692.896
Employees	750
EBITDA	-132M -290M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.28% upside

Market Stats
By TradingEconomics
Market Cap	4.9B 20B
Previous open	35.18
Previous close	30.17

News Sentiment

By Acuity

24%

76%

40 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

11 / 11.18 Support & Resistance

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 maj 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 maj 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 maj 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 maj 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 maj 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 maj 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 maj 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 maj 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 maj 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 maj 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 maj 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 maj 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 maj 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 maj 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 maj 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 maj 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 maj 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 maj 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 maj 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 maj 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

12.28% upside

12 Months Forecast

Average 36.39 USD 12.28%

High 42 USD

Low 29.5 USD

Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

40 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.